- Home
- RITR vs OKUR Comparison
RITR vs OKUR Comparison
Compare RITR & OKUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RITR
- OKUR
- Stock Information
- Founded
- RITR 2015
- OKUR 2011
- Country
- RITR Hong Kong
- OKUR United States
- Employees
- RITR N/A
- OKUR N/A
- Industry
- RITR
- OKUR
- Sector
- RITR
- OKUR
- Exchange
- RITR NYSE
- OKUR NYSE
- Market Cap
- RITR 276.0M
- OKUR 234.2M
- IPO Year
- RITR 2024
- OKUR N/A
- Fundamental
- Price
- RITR $7.66
- OKUR $18.83
- Analyst Decision
- RITR
- OKUR Strong Buy
- Analyst Count
- RITR 0
- OKUR 2
- Target Price
- RITR N/A
- OKUR $37.50
- AVG Volume (30 Days)
- RITR 172.1K
- OKUR 74.5K
- Earning Date
- RITR 11-03-2024
- OKUR 11-14-2024
- Dividend Yield
- RITR N/A
- OKUR N/A
- EPS Growth
- RITR N/A
- OKUR N/A
- EPS
- RITR 0.04
- OKUR N/A
- Revenue
- RITR $32,198,033.00
- OKUR N/A
- Revenue This Year
- RITR N/A
- OKUR N/A
- Revenue Next Year
- RITR N/A
- OKUR N/A
- P/E Ratio
- RITR $176.56
- OKUR N/A
- Revenue Growth
- RITR 74.80
- OKUR N/A
- 52 Week Low
- RITR $3.30
- OKUR $9.80
- 52 Week High
- RITR $8.38
- OKUR $82.90
- Technical
- Relative Strength Index (RSI)
- RITR N/A
- OKUR N/A
- Support Level
- RITR N/A
- OKUR N/A
- Resistance Level
- RITR N/A
- OKUR N/A
- Average True Range (ATR)
- RITR 0.00
- OKUR 0.00
- MACD
- RITR 0.00
- OKUR 0.00
- Stochastic Oscillator
- RITR 0.00
- OKUR 0.00
About RITR REITAR LOGTECH HLDGS LTD
Reitar Logtech Holdings Ltd provide one-stop solutions for logistics property operations in property development and redevelopment projects. It consists of two segments: construction management and engineering design services; and asset management and professional consultancy services in Hong Kong. Key revenue is generated from construction management and engineering design services.
About OKUR ONKURE THERAPEUTICS INC
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.